NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-04 22:34இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
PI Industries Q2 FY27: PAT Drops 70% to ₹122.2 Cr Amid Global Agchem Headwinds
PI Industries reported weak consolidated financial performance for Q2 FY27, with revenue declining 9% YoY to ₹1,701.8 Cr (INR 17,018 Mn) compared to ₹1,872.3 Cr in Q2 FY26. Profitability contracted sharply, as EBITDA fell 57% YoY to ₹236.2 Cr (margin shrunk to 14% from 29%) and Net Profit dropped 70% YoY to ₹122.2 Cr. The downturn was primarily driven by an 18% decline in agchem exports due to soft global demand, genericization, and inability to pass on input cost inflation, though domestic business rose 19% and global biologicals jumped 250%.
உச்சம் நம்பிக்கை
என்ன மாறியதுPI Industries published its Q2 FY27 earnings presentation detailing a sharp operational deceleration driven by global export headwinds and margin compression.
ஏன் இது முக்கியம்Agchem exports form the bulk of PI's revenue and profitability; pricing pressure from genericization and Chinese supply have severely eroded gross margins (down to 49% from 57%) and compressed earnings.
Q2 FY27 Revenue: ₹1,701.8 கோடிQ2 FY27 Net Profit: ₹122.2 கோடிQ2 FY27 EBITDA Margin: 14%Agchem Exports Decline: 18%Surplus Cash Net of Debt: ₹3,573.7 கோடிH1 FY27 Capex: ₹567.4 கோடி
📅 குறுகிய காலம்Near-term sentiment is likely to remain muted following a 70% drop in quarterly net profit and EBITDA margin compression to 14%.
📈 நீண்ட காலம்While agrochemical exports face cyclical and genericization headwinds, PI's balance sheet remains strong with ₹3,573.7 Cr in net cash, supporting investments in Pharma CDMO and high-growth biologicals.
⚠ அபாய எச்சரிக்கைகள்
Pricing pressure and channel inventory issues from global genericization and Chinese supplies
Inability to pass through cost escalations in the current export market environment
Overhead inflation from ongoing R&D and business development investments
👀 கவனிக்க வேண்டியவை
Track management commentary on export demand recovery, pricing stabilization in key agrochemical molecules, and the ramp-up of the commercialized API (Galidesivir) and biologicals portfolio in upcoming quarters.
PI Industries Q2 Standalone PAT Drops 57.8% YoY to ₹207.1 Cr; Revenue Down 12.5%
PI Industries reported its Q2 FY27 (quarter ended September 30, 2026) standalone financial results, showing a 12.5% YoY decline in revenue from operations to ₹1,533.5 Cr compared to ₹1,752.6 Cr in Q2 FY26. Standalone net profit fell steeply by 57.8% YoY to ₹207.1 Cr from ₹491.1 Cr in the prior-year period. Profit before tax stood at ₹275.2 Cr versus ₹614.6 Cr a year ago, reflecting ongoing margin contraction and industry headwinds. Half-year standalone net cash inflow from operations, however, remained healthy at ₹1,032.9 Cr, up from ₹343.3 Cr in H1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுPI Industries reported a significant YoY contraction in standalone revenue and net earnings for Q2 FY27.
ஏன் இது முக்கியம்The steep drop in profitability highlights persistent global agrochemical inventory destocking and pricing pressures, weighing on PI Industries' core CSM realizations.
📅 குறுகிய காலம்Weak quarterly earnings performance may keep the stock under pressure as margins continue to decline YoY.
📈 நீண்ட காலம்Long-term recovery hinges on the ramp-up of the biologicals and pharma CDMO portfolio alongside an order book execution of ~$1.4 billion.
⚠ அபாய எச்சரிக்கைகள்
Continued pressure on chemical realizations due to supply influx from China
Underperformance and losses across certain consolidated subsidiary operations
👀 கவனிக்க வேண்டியவை
Track the upcoming management earnings call for commentary on export demand recovery, pricing pressure from global generic supplies, and commercialization timelines of new molecules.
PI Industries Unveils Pioxaniliprole, India's First Indigenously Discovered Insecticide
PI Industries announced the unveiling of Pioxaniliprole, India's first indigenously discovered insecticide molecule, developed after more than a decade of research. The molecule has received formal registration from the Central Insecticides Board and Registration Committee (CIB&RC). PI's R&D capabilities backing the discovery include over 700 scientists, more than 200 PhDs, and a portfolio of over 260 patents. While commercial rollout timelines and potential revenue scale are not yet disclosed, proprietary IP molecules typically carry higher pricing power and margins compared to generic formulations.
உச்சம் நம்பிக்கை
என்ன மாறியதுPI Industries has successfully discovered and registered India's first indigenous insecticide active ingredient, Pioxaniliprole, via CIB&RC.
ஏன் இது முக்கியம்Demonstrates PI's transition from custom synthesis and manufacturing (CSM) of innovator molecules to originating its own proprietary, high-margin agricultural IP.
Research timeline: more than a decadeR&D scientific team: over 700 scientistsPhD scientific staff: more than 200 PhDsPatent portfolio: over 260 patents
📅 குறுகிய காலம்Positive sentiment driver for the stock given the validation of its in-house R&D capabilities, though direct near-term revenue impact will depend on launch timelines.
📈 நீண்ட காலம்Structurally enhances PI's product pipeline and margins by generating proprietary IP, reducing long-term dependence on third-party CSM partnerships.
⚠ அபாய எச்சரிக்கைகள்
Commercialization timeline and initial manufacturing ramp-up scale not disclosed
Market adoption and competitive pricing against existing insecticide classes
👀 கவனிக்க வேண்டியவை
Track management commentary in upcoming earnings calls regarding commercial launch dates, manufacturing rollout, domestic addressable market size, and international patent filings.
PI Industries Receives Registration for Indigenously Discovered Insecticide 'Pioxaniliprole'
PI Industries announced that it has received regulatory registration under section 9(3) of the Insecticides Act, 1968, for 'Pioxaniliprole' (branded as 'Pioxazon') for TIM and FIM categories. The approval stems from the 476th registration committee meeting held on September 10, 2026, and officially published on September 21, 2026. Described as India's first indigenously discovered and developed insecticide molecule, the product was created over a decade of R&D and will launch in the domestic market soon. This supports PI's broader strategy to expand its domestic branded formulations portfolio, which currently operates alongside its TTM revenue base of Rs 6,607 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுPI Industries received formal registration approval to manufacture and market its first indigenously discovered insecticide molecule, Pioxaniliprole ('Pioxazon'), in India.
ஏன் இது முக்கியம்Marks a major shift from contract research/manufacturing to commercializing self-discovered proprietary IP, potentially bolstering domestic market share and proprietary formulation margins.
Meeting reference: 476th registration committee meetingMeeting date: செப்டம்பர் 10, 2026Registration notification date: செப்டம்பர் 21, 2026TTM Revenue context: Rs 6,607 கோடி
📅 குறுகிய காலம்Positive sentiment driver as the regulatory hurdle is cleared; commercial revenue contribution will depend on distribution ramp-up and pricing details upon launch.
📈 நீண்ட காலம்Validates PI's R&D capabilities in discovering novel chemical entities, supporting its strategic transition toward proprietary IP and margin-accretive branded formulations.
⚠ அபாய எச்சரிக்கைகள்
Market adoption and competitive pricing dynamics against established alternatives
Exposure to domestic agrochemical demand fluctuations and monsoon performance
👀 கவனிக்க வேண்டியவை
Track the commercial rollout timeline of Pioxazon in upcoming quarters and management commentary on domestic market revenue potential and gross margin contributions.
PI Industries Q1 FY27: PAT Drops 39% to ₹244 Cr Amid Export Headwinds
PI Industries reported a weak Q1 FY27 with consolidated revenue declining 10% YoY to ₹17,023 Mn, primarily due to a 12% drop in Agchem exports. Profitability was significantly impacted as EBITDA fell 29% to ₹3,693 Mn and PAT dropped 39% to ₹2,442 Mn, driven by pricing pressures and higher input costs. Despite global disruptions, domestic volumes grew 12% and the biologicals segment surged over 50% YoY. The company remains financially robust with a net cash surplus of ₹37,939 Mn and continued its investment strategy with a Q1 capex of ₹2,685 Mn.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company transitioned from high growth to a cyclical downturn in its core export business, leading to significant margin compression.
ஏன் இது முக்கியம்As a leading CSM player, the 12% drop in PI's exports signals persistent global inventory issues and pricing pressure, testing the company's ability to pivot toward its newer Pharma and Biological segments.
📅 குறுகிய காலம்The stock may face downward pressure in the near term due to the significant miss in PAT and EBITDA margins compared to the previous year.
📈 நீண்ட காலம்The structural shift toward Biologicals and Pharma CDMO remains intact, but the recovery of the core Agchem export business is critical for returning to historical growth rates.
⚠ அபாய எச்சரிக்கைகள்
Global agrochemical demand softness
Pricing pressure from Chinese supply deluge
Order phasing delays in Pharma (PIHS) segment
Input cost inflation due to geopolitical issues
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery timeline for global agrochemical demand and the stabilization of export margins, while tracking the execution of the 20+ products currently in the innovation pipeline.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
PI Industries Q1 Revenue Declines 10.4% to ₹1,702 Cr; Forms CSR Subsidiary
PI Industries reported a consolidated revenue of ₹1,702.3 Cr for Q1 FY27, marking a 10.4% decline from ₹1,900.5 Cr in Q1 FY26. Standalone net profit for the quarter fell significantly to ₹341.5 Cr compared to ₹464.3 Cr in the same period last year. The company also announced the incorporation of 'PI Foundation', a wholly-owned Section 8 subsidiary dedicated to CSR activities with a nominal initial capital of ₹1 lakh. These results reflect ongoing headwinds in the agrochemical sector, despite the company's robust ₹13,000 Cr (USD 1.4 billion) order book.
உச்சம் நம்பிக்கை
என்ன மாறியதுPI Industries reported a year-on-year decline in both revenue and profitability for the June 2026 quarter and formalized its CSR operations into a separate subsidiary.
ஏன் இது முக்கியம்The revenue and profit contraction indicates that even high-quality CSM players like PI Industries are not immune to the current global agrochemical slowdown and pricing pressures. The formation of the Section 8 company is a routine administrative step for CSR compliance.
Q1 Consolidated Revenue: ₹1,702.3 கோடிRevenue Growth (YoY): -10.4%Standalone EPS (Q1): ₹22.50Q1 வருவாய் vs TTM வருவாய்: 25.7%PI Foundation Initial Capital: ₹1,00,000
📅 குறுகிய காலம்The stock is likely to face downward pressure in the short term as the market reacts to the double-digit revenue decline and lower-than-expected profitability.
📈 நீண்ட காலம்The long-term outlook depends on the company's ability to diversify into Pharma CDMO and Biologicals and the successful commercialization of its molecule pipeline to offset agrochemical volatility.
⚠ அபாய எச்சரிக்கைகள்
Global agrochemical industry slowdown
Pricing pressure from Chinese exports
Execution risk in the new Pharma CDMO segment
👀 கவனிக்க வேண்டியவை
Investors should monitor management commentary regarding the 'supply deluge from China' and its impact on pricing realizations. Key to recovery will be the execution of the USD 1.4 billion order book and the ramp-up of the newly acquired pharma and biological entities.
Rs 10 Final Dividend: PI Industries Sets August 7, 2026, as Record Date
PI Industries has announced August 7, 2026, as the record date for a final dividend of Rs 10 per equity share for the financial year 2025-26. The dividend is subject to shareholder approval at the upcoming 79th Annual General Meeting (AGM) scheduled for August 14, 2026. Based on the current market price of Rs 2,631.8, this represents a dividend yield of approximately 0.38%. The company continues to maintain a strong balance sheet with a cash surplus of Rs 4,158 Cr available for future acquisitions.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has finalized the specific dates for its previously proposed final dividend and its 79th Annual General Meeting.
ஏன் இது முக்கியம்This is a routine distribution of profits to shareholders, reflecting the company's consistent payout policy despite a 35.6% decline in share price over the last 12 months.
Final Dividend: Rs 10 per shareரெக்கார்ட் தேதி: ஆகஸ்ட் 7, 2026டிவிடெண்ட் ஈல்ட்: ~0.38%TTM EPS: Rs 85.11Cash Surplus: Rs 4,158 கோடி
📅 குறுகிய காலம்The stock may trade ex-dividend a day or two prior to August 7, which typically results in a minor price adjustment equal to the dividend amount.
📈 நீண்ட காலம்Limited structural significance; the focus remains on the company's ability to scale its Pharma CDMO and Biologicals segments to offset agrochemical volatility.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend must hold the shares in their demat account by the record date of August 7, 2026. Monitor the AGM on August 14 for updates on the execution of the USD 1.4 billion order book.
PI Industries Converts Rs 1,000 Cr OFCDs into Equity in PI Health Sciences Subsidiary
PI Industries has exercised its option to convert Rs 10,000 million (Rs 1,000 crore) worth of Optionally Fully Convertible Debentures (OFCDs) into equity shares of its wholly-owned subsidiary, PI Health Sciences Limited (PIHS). The conversion results in the issuance of 72.46 crore equity shares at a fair value of Rs 13.80 per share. This internal restructuring does not involve any cash outflow or change in ownership, as PIHS remains a 100% subsidiary. The move is intended to strengthen the consolidated balance sheet and support the subsidiary's Pharma CRDMO business.
முக்கிய அம்சங்கள்
Conversion of Rs 10,000 million (Rs 1,000 crore) OFCDs into equity shares of PI Health SciencesIssuance of 72,46,37,687 equity shares at a fair value of Rs 13.80 per sharePI Health Sciences remains a 100% wholly-owned subsidiary with no change in controlTransaction involves no cash consideration or external share swapAims to strengthen the consolidated balance sheet and support the Pharma CRDMO segment
👀 கவனிக்க வேண்டியவை
This is a routine internal capital restructuring with no immediate impact on cash flows or valuation. Investors should focus on the operational growth of the Pharma CRDMO subsidiary as it scales its turnover.
PI Industries FY26 Revenue at ₹67,137 Mn; Pharma Grows 40% Amid AgChem Downcycle
PI Industries reported FY26 revenue of ₹67,137 million, maintaining a steady 25% EBITDA margin despite a challenging global agrochemical downcycle. The Pharma segment emerged as a high-growth engine with 40% annual growth, while Biologicals continued to compound at over 20%. The company maintains a robust debt-free balance sheet with ₹34,265 million in net cash. Management expects a recovery in exports by H2 FY27, supported by the launch of their first homegrown New Chemical Entity (NCE), Pioxaniliprole.
முக்கிய அம்சங்கள்
FY26 consolidated revenue reached ₹67,137 million with a resilient EBITDA margin of 25%.Pharma business delivered 40% growth in FY26, driven by strategic customer onboarding and CRDMO scaling.Maintained a strong liquidity position with net cash of ₹34,265 million for future strategic investments.New products now contribute 18% of total AgChem exports, highlighting successful portfolio de-risking.First proprietary NCE, Pioxaniliprole, is set for market entry to transition the company toward an innovator model.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial ramp-up of the new NCE and the recovery of export volumes in H2 FY27. The strong cash position provides significant optionality for M&A or further expansion into Life Sciences and Electronic Chemicals.
PI Industries Q4 FY26 Revenue Down 12% to ₹15,652 Mn; Final Dividend of ₹10 Declared
PI Industries reported a challenging Q4 FY26 with consolidated revenue declining 12% YoY to ₹15,652 Mn, primarily due to a 15% contraction in Agchem exports. EBITDA margins contracted to 22% from 26% a year ago, while PAT fell 39% to ₹2,002 Mn. Despite the cyclical downturn in the global agrochemical industry, the Pharma segment showed resilience with 40% annual growth in FY26. The company maintains a strong balance sheet with surplus cash of ₹34,265 Mn and has proposed a final dividend of ₹10 per share.
முக்கிய அம்சங்கள்
Q4 Revenue fell 12% YoY to ₹15,652 Mn; FY26 Revenue declined 16% to ₹67,137 Mn.EBITDA for Q4 dropped 26% YoY to ₹3,373 Mn with margins contracting by 402 bps to 22%.Pharma segment revenue grew 40% YoY in FY26, now contributing ~6% of total exports.Board recommended a final dividend of ₹10 per share, taking the total FY26 dividend to ₹15.Maintained a robust cash position of ₹34,265 Mn despite a high FY26 capex of ₹11,508 Mn.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery in global agrochemical demand and the scaling of the Pharma business, which is successfully diversifying the revenue mix. While cyclical headwinds persist, the company's strong cash reserves and innovation pipeline support long-term value compounding.
PI Industries FY26 Profit Drops 23% to ₹14,348 Million; Declares ₹10 Final Dividend
PI Industries reported a significant decline in its financial performance for the fiscal year ended March 31, 2026, with standalone revenue falling 18.3% to ₹61,827 million. Net profit followed suit, dropping from ₹18,665 million in FY25 to ₹14,348 million in FY26. Despite the earnings contraction, the board recommended a final dividend of ₹10 per share, bringing the total FY26 dividend to ₹15. The company also announced a major leadership transition, including the resignation of the Joint Managing Director and the appointment of a new Whole-time Director.
முக்கிய அம்சங்கள்
Standalone Revenue from operations declined to ₹61,827 million in FY26 from ₹75,712 million in FY25.Net Profit for the full year decreased by 23.1% YoY to ₹14,348 million.Recommended a final dividend of ₹10 per share (1000%), totaling ₹15 for the full fiscal year.Mr. Rajnish Sarna resigned as Joint Managing Director, transitioning to a Non-Executive role.Dr. Atul Kumar Gupta appointed as Whole-time Director for a 3-year term effective May 19, 2026.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the sharp decline in annual revenue and profitability. Monitor management's guidance on recovery timelines and the impact of the significant leadership reshuffle on future operations.
PI Industries Q3 FY26: Pharma Grows 50%, Gross Margins Expand to 59% Amid AgChem Headwinds
PI Industries reported Q3 FY26 revenue of INR 13,757 million, navigating a prolonged global AgChem down cycle and distributor destocking. While AgChem exports moderated, the Pharma segment delivered a robust 50% growth over the nine-month period. Gross margins expanded to 59% due to a favorable product mix and cost discipline, while EBITDA margins remained resilient at 27%. The company maintains a strong, debt-free balance sheet with net cash of INR 35 billion, supporting future strategic investments.
முக்கிய அம்சங்கள்
Q3 FY26 revenue reached INR 13,757 million with gross margins expanding to 59%.Pharma business segment delivered 50% year-on-year growth during the nine-month period.Net cash position stands at INR 35 billion with a completely debt-free balance sheet.Exceptional income of INR 1,260 million recorded from a pharma contingent consideration write-back.Commercialized 5 new molecules in AgChem exports and 4 in the domestic market during the year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the management's guidance of a recovery starting in Q4 FY26 and growth momentum in FY27. The strong cash reserves and expansion into Pharma and Biologicals provide a diversified growth cushion against AgChem cyclicality.
PI Industries Q3 FY26: Revenue Drops 28% YoY Amid Export Phasing; Pharma Grows 50% in 9M
PI Industries reported a weak Q3 FY26 with consolidated revenue declining 28% YoY to ₹13,757 million, primarily driven by a 32% drop in Agchem exports due to customer delivery phasing. EBITDA margins contracted by 495 bps to 22%, although gross margins improved significantly by 631 bps to 59% due to a favorable product mix. The Pharma segment remains a bright spot, posting 50% YoY growth for 9M FY26. The company maintains a strong, debt-free balance sheet with a cash surplus of ₹35,066 million and declared an interim dividend of ₹5.00 per share.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue fell 28% YoY to ₹13,757 Mn, while EBITDA declined 41% to ₹3,027 Mn.Agchem Exports volume decreased 29% in Q3, impacted by delivery schedules and high base effects.Pharma vertical revenue grew 50% YoY in 9M FY26 to ₹1,957 Mn, now contributing ~5% of exports.Net Profit of ₹3,113 Mn includes an exceptional writeback of ₹1,260 Mn in contingent consideration.9M FY26 Capex stood at ₹7,225 Mn, focusing on manufacturing and R&D infrastructure.
👀 கவனிக்க வேண்டியவை
Investors should watch for a volume recovery in Q4 as management indicates the Q3 decline was largely due to timing and delivery phasing. The rapid growth in the Pharma and Biologicals segments offers long-term diversification, but near-term stock performance may be pressured by the core Agchem slowdown.
PI Industries Declares Rs 5 Interim Dividend; Sets Feb 23, 2026 as Record Date
PI Industries has declared an interim dividend of Rs 5 per equity share (500% of face value) for the financial year 2025-26. The company has fixed February 23, 2026, as the record date to determine eligible shareholders for this payout. Investors are required to submit tax-related documents by February 21, 2026, to ensure appropriate TDS rates are applied. Notably, the company will now process all dividend payments exclusively through electronic modes as per SEBI regulations.
முக்கிய அம்சங்கள்
Interim dividend of Rs 5 per equity share of face value Re 1 declared for FY 2025-26Record date for determining shareholder eligibility is fixed as February 23, 2026Standard TDS of 10% for resident shareholders with PAN; 20% for those without valid PAN/Aadhaar linkTDS exemption available for resident individuals if total dividend for FY 2025-26 does not exceed Rs 10,000Deadline for submission of tax exemption forms (15G/15H) and other documents is February 21, 2026
👀 கவனிக்க வேண்டியவை
Shareholders should ensure their bank account and KYC details are updated with their Depository Participant or RTA to receive the dividend electronically. Eligible investors should submit Form 15G/15H by February 21 to avoid higher tax deductions.
PI Industries reported a significant decline in consolidated revenue for Q3 FY26, falling to ₹13,757 million from ₹19,008 million in the previous year. Consolidated net profit also decreased to ₹3,113 million compared to ₹3,727 million YoY, despite a net exceptional gain of ₹1,051 million. To reward shareholders, the board declared an interim dividend of ₹5 per share (500% of face value) with a record date of February 23, 2026. The company also recognized a ₹206 million exceptional charge on a standalone basis due to the implementation of New Labour Codes.
முக்கிய அம்சங்கள்
Consolidated revenue from operations declined 27.6% YoY to ₹13,757 million.Consolidated PAT for the quarter stood at ₹3,113 million, down 16.5% from ₹3,727 million YoY.Interim dividend of ₹5 per equity share (500%) declared with a record date of Feb 23, 2026.Exceptional gain of ₹1,051 million reported in consolidated results for the quarter.Basic EPS decreased to ₹20.52 from ₹24.55 in the corresponding quarter of the previous year.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the sharp decline in top-line growth and margins indicates headwinds in the agrochemical sector. While the ₹5 dividend provides some immediate yield, the focus should remain on management's outlook for demand recovery.
PI Industries Q3 Net Profit Falls 16.5% to ₹311 Cr; Declares ₹5 Interim Dividend
PI Industries reported a weak set of numbers for Q3 FY26, with consolidated revenue from operations declining 27.6% YoY to ₹13,757 million. Consolidated net profit for the quarter fell 16.5% to ₹3,113 million, even after accounting for a net exceptional gain of ₹1,051 million. The company declared an interim dividend of ₹5 per share (500% of face value) with a record date of February 23, 2026. Standalone performance mirrored the consolidated trend, with revenue dropping nearly 29% YoY, reflecting significant headwinds in the agrochemical sector.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations dropped 27.6% YoY to ₹13,757 million from ₹19,008 million in the previous year.Consolidated Net Profit decreased by 16.5% YoY to ₹3,113 million, supported by an exceptional gain of ₹1,051 million.Declared an interim dividend of ₹5 per equity share for FY 2025-26, payable by March 13, 2026.Standalone results included an exceptional loss of ₹206 million due to the implementation of New Labour Codes.The company confirmed that the entire ₹20,000 million raised through QIP in 2020 has now been fully utilized.
👀 கவனிக்க வேண்டியவை
The significant decline in both top-line and bottom-line performance suggests a challenging environment for the company's core agrochemical business. Investors should exercise caution and wait for management commentary on demand recovery and the nature of the consolidated exceptional gain before making new entries.
PI Industries Appoints Syngenta Veteran Kamali Rajesh as Global CPO
PI Industries has announced the appointment of Ms. Kamali Rajesh as the Global Chief People Officer (CPO) and Senior Management Personnel, effective January 19, 2026. She succeeds Mr. Balasubramaniam Aiyaswamy, who will cease his role on the same date. Ms. Rajesh brings over 25 years of global HR experience, most recently serving as a senior leader at Syngenta Group, a major global agriscience peer. This transition is aimed at driving transformation and organizational agility as the company expands its global footprint.
முக்கிய அம்சங்கள்
Ms. Kamali Rajesh appointed as Global Chief People Officer effective January 19, 2026.Brings over 25 years of HR leadership experience across Asia, Europe, the US, and Africa.Previously served as Global Head of People & Organisation Development at Syngenta Group.Mr. Balasubramaniam Aiyaswamy to step down from the Senior Management Personnel role on January 19, 2026.Ms. Rajesh has extensive experience in the agritech, automotive, and IT sectors.
👀 கவனிக்க வேண்டியவை
Investors should view the hiring of a high-profile leader from a global competitor like Syngenta as a positive move for PI's long-term organizational strategy. No immediate portfolio changes are necessary based on this management update.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
